Cymabay Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview

CymaBay Therapeutics

14/03/2023 20:23

* Cymabay Therapeutics Inc  CBAY.OQ   CBAY.O  is expected
to show
no change in quarterly revenue when it reports  results on March
16. 
    * 
    * ​Refinitiv's mean analyst estimate for Cymabay
Therapeutics Inc
is for a loss of 30 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cymabay
Therapeutics Inc is $12​, above​ its last closing price
of $8.94. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.30       -0.30      -0.28     Beat    7
 Jun. 30 2022  -0.30       -0.30      -0.31     Missed  -3.8
 Mar. 31 2022  -0.31       -0.31      -0.32     Missed  -3.3​
 Dec. 31 2021              -0.26      -0.34     Missed  -30.1
 ​​Sep.        -0.28       -0.26      -0.33     Missed  -25.4
 30 2021                                                
 Jun. 30 2021  -0.27       -0.27      -0.34     Missed  -27​
 Mar. 31 2021  -0.25       -0.24      -0.25     Missed  -2.4
 Dec. 31 2020              -0.20      -0.23     Missed  -14.9
 This summary was machine generated March 14 at 20:23 GMT.  All
figures in US dollars  unless otherwise stated